Naseem Amin - 07 Jun 2023 Form 4 Insider Report for Bellerophon Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2023, 16:12:24 UTC
Prior SEC filing: 14 Feb 2023
Next SEC filing: 21 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Naseem Amin

Key filing fact

Naseem Amin filed Form 4 for Bellerophon Therapeutics, Inc. on 09 Jun 2023.

Key facts

This page summarizes Naseem Amin's Form 4 filing for Bellerophon Therapeutics, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jun 2023, 16:12.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLPH transaction

Common Stock

Award

Transaction value: $0
Shares: +47,578
Change %: +19%
Price: $0.000000
Shares after: 291,865
Date: 07 Jun 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents 47,578 restricted stock units granted under the Issuer's 2015 Equity Incentive Compensation Plan. The restricted stock units vest in full on December 31, 2023. This grant of restricted stock units was approved by the Compensation Committee of the Board of Directors of the Issuer on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the restricted stock units were granted, which was approved by stockholders on June 7, 2023.